A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Lot Consistency Trial)
An Randomized, Double-blinded Trial of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® to Evaluate Lot-to-lot Consistency
Sponsor: Jiangsu Province Centers for Disease Control and Prevention
Listed as NCT03365921, this PHASE4 trial focuses on Hepatitis E and remains completed. Sponsored by Jiangsu Province Centers for Disease Control and Prevention, it has been updated 7 times since 2018, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE4
Status: Withdrawn → Completed
-
Jun 2018 — Jun 2020 [monthly]
Withdrawn PHASE4
▶ Show 2 earlier versions
-
Feb 2018 — Jun 2018 [monthly]
Withdrawn PHASE4
Status: Not Yet Recruiting → Withdrawn
-
Dec 2017 — Feb 2018 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu Province Centers for Disease Control and Prevention
- Xiamen Innovax Biotech Co., Ltd
For direct contact, visit the study record on ClinicalTrials.gov .